For Payors

Innovation backed
by clinical evidence.

Evidence demonstrates that Guidance® UTI is associated with a 13.7% reduction in Emergency Department visits and hospitalizations.1 A reduction in UTI-related hospitalizations leads to significant savings — approximately $65,000 saved for each patient avoiding admission.2

Download Full Infographic (PDF) Real World Evidence
Real World Evidence

Reductions in critical adverse outcomes, healthcare resource utilization, and cost for complicated UTI.

Study size: standard urine culture (N=678) or Guidance® UTI (N=69)

13%

Lower rate of outpatient emergency visits

67%

Lower inpatient admissions rate

NO

Urosepsis, urgent care & SNF admissions per 1,000 patients

$463

Savings per cUTI patient (p=0.043)

42%

Reduction in ED, inpatient, urgent care & SNF visits

$11.6M

Savings for 25,000 cUTI cases

Download Full Infographic (PDF)
The Cost of Getting It Wrong

UTIs are expensive — for systems and patients.

Cost for Healthcare System

  • UTIs are responsible for 10.5 million office visits per year.3
  • 3.1 million ER visits per year.4
  • UTIs are the 4th leading cause of hospitalization for Medicare patients, with 200,000 hospitalizations annually.5

Cost for Patient Outcomes

  • Up to 1/3 of infections illustrate resistance to an antibiotic.6
  • Antibiotic resistance gives rise to at least 2 million infections and 23,000 deaths/year (CDC).7

Bypass challenges with Guidance® UTI

Guidance® UTI empowers health systems to rapidly detect and treat UTIs — a 13.7% decrease in hospital admissions was reported.8

vs. Traditional urine culture

Traditional urine culture misses up to 22% of all UTI-positive patients.1 Guidance® UTI detected 43% more organisms than culture3, covering the most relevant causes of UTIs for a more accurate diagnosis.

vs. Genotype testing alone

Genotype testing alone only reports on the genetic potential to develop resistance to antibiotics, which may not be enough information to guide effective treatment. Guidance® UTI is the only test that goes beyond genotype testing by including patented Pooled Antibiotic Susceptibility Testing (P-AST™). P-AST™ accounts for bacterial interactions in polymicrobial infections that may alter antibiotic resistance.

vs. Delayed personalized treatment

Delayed personalized treatment happens consistently with traditional culture methods taking up to three days or more to return results. Guidance® UTI delivers results in less than one day of a sample reaching the lab — for fast, personalized treatment that advances patient outcomes and antibiotic stewardship.

See clinical resources →

Need more information on the economics?

Talk to a Pathnostics representative or browse the underlying evidence.

Talk to a Representative Clinical Resources
References
  1. Daly A, Baunoch D, Rehling K, Luke N, Campbell M, et al. (2020). Utilization of M-PCR and P-AST for Diagnosis and Management of Urinary Tract Infections in Home-Based Primary Care. JOJ Urology & Nephrology, 7(2), 555707. DOI: 10.19080/JOJUN.2020.07.555707
  2. Turner RM, Wu B, Lawrence K, Hackett J, Karve S, et al. (2015). Assessment of Outpatient and Inpatient Antibiotic Treatment Patterns and Health Care Costs of Patients with Complicated Urinary Tract Infections. Clinical Therapeutics, 37(9): 2037-2047.
  3. Vollstedt A, Baunoch D, Wojno KJ, Luke N, Cline K, et al. (2020). Multisite Prospective Comparison of Multiplex Polymerase Chain Reaction Testing with Urine Culture for Diagnosis of Urinary Tract Infections in Symptomatic Patients. J Sur Urology, JSU-102. DOI: 10.29011/JSU-102.100002
  4. CDC — National Center for Health Statistics, 2017.
  5. Data.CMS.gov National Summary of Inpatient Charge Data by Medicare Severity Diagnosis Related Group (MS-DRG), FY2017. Centers for Medicare & Medicaid Services. data.cms.gov
  6. Schmiemann G, et al. Resistance profiles of urinary tract infections in general practice — an observational study. BMC Urol. 2012;12:33.
  7. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. cdc.gov/drugresistance/threat-report-2013-508.pdf
  8. Daly A, Baunoch D, Rehling K, Luke N, Campbell M, et al. Utilization of M-PCR and P-AST for Diagnosis and Management of Urinary Tract Infections in Home-Based Primary Care. JOJ Urology & Nephrology. 2020;7(2):555707. DOI: 10.19080/JOJUN.2020.07.555707
  9. Ashok A, Ko D, Lukacz E, Vollstedt A, Juster I, Niecko T, Baunoch D, Mathur M. Comparison of Guidance® UTI and standard urine culture for rates of sepsis, hospitalization and other adverse outcomes in complicated urinary tract infections. Journal of Urology, AUA Annual Meeting Program Abstracts 2022. May 2022. Volume 207 Issue Supplement 5.